{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:54Z","timestamp":1790155734608,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.ymgme.2007.10.001","type":"journal-article","created":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T08:25:38Z","timestamp":1196497538000},"page":"331-340","source":"Crossref","is-referenced-by-count":81,"title":["Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease"],"prefix":"10.1016","volume":"93","author":[{"given":"Christiane","family":"Auray-Blais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9","family":"Ntwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josanne","family":"Cox-Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Laframboise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge B.","family":"Melan\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe T.R.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gen","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2007.10.001_bib1","first-page":"739","volume":"284","author":"Desnick","year":"1971","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2007.10.001_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2007.10.001_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2007.10.001_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2007.10.001_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2007.10.001_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry\u2019s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"10.1016\/j.ymgme.2007.10.001_bib7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2007.10.001_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08035320510031045","article-title":"Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry outcome survey","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2007.10.001_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2007.10.001_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF00223869","article-title":"Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins","volume":"95","author":"Okumiya","year":"1995","journal-title":"Hum. Genet."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2007.10.001_bib11","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1097\/01.ASN.0000015236.70757.C4","article-title":"Biochemical and molecular genetic basis of Fabry disease","volume":"13","author":"Pastores","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2007.10.001_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2001.600107.x","article-title":"Identification of fifteen novel mutations and genotype\u2013phenotype relationship in Fabry disease","volume":"60","author":"Altarescu","year":"2001","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2007.10.001_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymgme.2007.10.001_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF02267068","article-title":"Novel trinucleotide deletion in Fabry\u2019s disease","volume":"97","author":"Cariolou","year":"1996","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2007.10.001_bib15","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2007.10.001_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"Shabbeer","year":"2006","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.ymgme.2007.10.001_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03402156","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations and genotype\u2013phenotype correlations in classical and variant phenotypes","volume":"8","author":"Germain","year":"2002","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2007.10.001_bib18","first-page":"227","article-title":"Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"Ashton-Prolla","year":"2000","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.ymgme.2007.10.001_bib19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<420::AID-AJMG6>3.0.CO;2-Z","article-title":"Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG)","volume":"84","author":"Ashton-Prolla","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2007.10.001_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI114027","article-title":"Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene","volume":"83","author":"Bernstein","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2007.10.001_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2007.10.001_bib22","first-page":"57","article-title":"Clinical development of agalsidase-beta for the treatment of Fabry disease","volume":"21","author":"Germain","year":"2005","journal-title":"Med. Sci."},{"key":"10.1016\/j.ymgme.2007.10.001_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2007.10.001_bib24","first-page":"77","article-title":"Enzyme replacement therapies for lysosomal storage disorders","volume":"21","author":"Germain","year":"2005","journal-title":"Med. Sci."},{"key":"10.1016\/j.ymgme.2007.10.001_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7326\/0003-4819-146-2-200701160-00147","article-title":"Enzyme replacement in Fabry disease: the essence is in the kidney","volume":"146","author":"Schiffmann","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2007.10.001_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","article-title":"Cellular and tissue distribution of intravenously administered agalsidase alfa","volume":"90","author":"Murray","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2007.10.001_bib27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2007.10.001_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2007.10.001_bib29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/rcm.728","article-title":"Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease","volume":"16","author":"Boscaro","year":"2002","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ymgme.2007.10.001_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/rcm.1948","article-title":"Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard","volume":"19","author":"Fauler","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ymgme.2007.10.001_bib31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2007.10.001_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2007.10.001_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2007.10.001_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2004.038323","article-title":"Liquid chromatography\u2013tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy","volume":"51","author":"Roddy","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2007.10.001_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2007.10.001_bib36","first-page":"207","article-title":"Determination of creatinine by means of automatic chemical analysis","volume":"30","author":"Chasson","year":"1960","journal-title":"Tech. Bull. Regist. Med. Technol."},{"key":"10.1016\/j.ymgme.2007.10.001_bib37","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1186\/1472-6939-7-4","article-title":"A biobank management model applicable to biomedical research","volume":"7","author":"Auray-Blais","year":"2006","journal-title":"BMC Med. Ethics"},{"key":"10.1016\/j.ymgme.2007.10.001_bib38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jmg.33.8.682","article-title":"Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene","volume":"33","author":"Redonnet-Vernhet","year":"1996","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2007.10.001_bib39","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am. J. Hum. Genet."},{"issue":"439S","key":"10.1016\/j.ymgme.2007.10.001_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1651-2227.2002.tb03123.x","article-title":"A Nova Scotia kindred with Fabry disease","volume":"91","author":"West","year":"2002","journal-title":"Acta Paed."},{"key":"10.1016\/j.ymgme.2007.10.001_bib41","first-page":"108","article-title":"A Fabry disease homozygote in the Nova Scotia kindred with a classic hemizygote phenotype","volume":"443","author":"Thanamayooran","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2007.10.001_bib42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2007.10.001_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cccn.2005.04.036","article-title":"Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments","volume":"360","author":"Utsumi","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2007.10.001_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1258\/000456306776021544","article-title":"Validation of a liquid chromatography tandem mass spectrometry assay for serum creatinine and comparison with enzymatic and Jaffe methods","volume":"43","author":"Owen","year":"2006","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ymgme.2007.10.001_bib45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00007691-200212000-00013","article-title":"Simultaneous and rapid analysis of cyclosporin A and creatinine in finger prick blood samples using liquid chromatography tandem mass spectrometry and its application in C2 monitoring","volume":"24","author":"Keevil","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ymgme.2007.10.001_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cca.2005.06.016","article-title":"Quantitative determination of guanidinoacetate and creatine in dried blood spot by flow injection analysis-electrospray tandem mass spectrometry","volume":"364","author":"Carducci","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2007.10.001_bib47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/humu.9327","article-title":"Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease","volume":"25","author":"Schafer","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2007.10.001_bib48","series-title":"Fabry disease. Perspectives from 5 years of FOS","article-title":"Biochemical and genetic diagnosis of Fabry disease","author":"Winchester","year":"2006"},{"key":"10.1016\/j.ymgme.2007.10.001_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1651-2227.2006.00219_1.x","article-title":"Fabry disease: genotype\u2013phenotype studies; epidemiology; screening and management","volume":"96","author":"Azcona","year":"2007","journal-title":"Acta Paediatr. Suppl."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719207004428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719207004428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T22:57:17Z","timestamp":1708383437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719207004428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S1096719207004428"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2007.10.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}